Cargando…
Absorption, distribution, metabolism and excretion of molidustat in healthy participants
The absorption, distribution, metabolism and excretion of molidustat were investigated in healthy male participants. In study 1, a mass balance study, radiolabelled molidustat 25 mg (3.57 MBq) was administered as an oral solution (n = 4). Following rapid absorption, molidustat‐related radioactivity...
Autores principales: | Lentini, Silvia, van der Mey, Dorina, Kern, Armin, Thuss, Uwe, Kaiser, Andreas, Matsuno, Kumi, Gerisch, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496954/ https://www.ncbi.nlm.nih.gov/pubmed/32248614 http://dx.doi.org/10.1111/bcpt.13409 |
Ejemplares similares
-
Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human
por: van der Mey, Dorina, et al.
Publicado: (2020) -
Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects
por: Flamme, Ingo, et al.
Publicado: (2014) -
Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
por: Akizawa, Tadao, et al.
Publicado: (2021) -
Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021) -
Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia
por: Beck, Hartmut, et al.
Publicado: (2018)